Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Seong Hee | - |
dc.contributor.author | Cho, Dong-Hyuk | - |
dc.contributor.author | Choi, Jimi | - |
dc.contributor.author | Baik, Soon Koo | - |
dc.contributor.author | Gwon, Jun Gyo | - |
dc.contributor.author | Kim, Moon Young | - |
dc.date.accessioned | 2022-03-10T15:40:48Z | - |
dc.date.available | 2022-03-10T15:40:48Z | - |
dc.date.created | 2022-02-09 | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/138482 | - |
dc.description.abstract | Background/Aims We measured the association between underlying chronic hepatitis B (CHB) and antiviral use with infection rates among patients who underwent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing. Methods In total, 204,418 patients who were tested for SARS-CoV-2 between January and June 2020 were included. For each case patient (n = 7,723) with a positive SARS-CoV-2 test, random controls (n = 46,231) were selected from the target population who had been exposed to someone with coronavirus disease 2019 (COVID-19) but had a negative SARS-CoV-2 test result. We merged claim-based data from the Korean National Health Insurance Service database collected. Primary endpoints were SARS-CoV-2 infection and severe clinical outcomes of COVID-19. Results The proportion of underlying CHB was lower in COVID-19 positive patients (n = 267, 3.5%) than in COVID-19 negative controls (n = 2482, 5.4%). Underlying CHB was associated with a lower SARS-CoV-2 positivity rate, after adjusting for comorbidities (adjusted odds ratio [aOR] 0.65; 95% confidence interval [CI], 0.57-0.74). Among patients with confirmed COVID-19, underlying CHB tended to confer a 66% greater risk of severe clinical outcomes of COVID-19, although this value was statistically insignificant. Antiviral treatment including tenofovir and entecavir was associated with a reduced SARS-CoV-2 positivity rate (aOR 0.49; 95% CI, 0.37-0.66), while treatment was not associated with severe clinical outcomes of COVID-19. Conclusions Underlying CHB and antiviral agents including tenofovir decreased susceptibility to SARS-CoV-2 infection. HBV coinfection did not increase the risk of disease severity or lead to a worse prognosis in COVID-19. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PUBLIC LIBRARY SCIENCE | - |
dc.subject | CLINICAL-OUTCOMES | - |
dc.title | Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Gwon, Jun Gyo | - |
dc.identifier.doi | 10.1371/journal.pone.0258229 | - |
dc.identifier.scopusid | 2-s2.0-85116526112 | - |
dc.identifier.wosid | 000733418800007 | - |
dc.identifier.bibliographicCitation | PLOS ONE, v.16, no.10 | - |
dc.relation.isPartOf | PLOS ONE | - |
dc.citation.title | PLOS ONE | - |
dc.citation.volume | 16 | - |
dc.citation.number | 10 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | CLINICAL-OUTCOMES | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.